Indications and usage of Binimetinib

Binimetinib (Binimetinib) in combination with canafenib (Encorafenib) for the treatment of BRAF detected in a test approved by the U.S. Food and Drug Administration (FDA) Patients with unresectable or metastatic melanoma with a V600E or V600K mutation, is also indicated for the treatment of adult patients with BRAF V600E-mutated metastatic non-small cell lung cancer, and must be used in combination with canafenib , as detected by an FDA-approved test.

The pharmacokinetics of bimetinib were studied in healthy subjects and patients with solid tumors. After dosing twice daily, the cumulative amount is 1.5 times, and the coefficient of variation (CV%) of the area under the concentration-time curve (AUC) is <40% at steady state. After oral administration, at least 50% of the bimetinib dose is absorbed, with a median time to maximum concentration (Tmax) of 1.6 hours. Bimetinibis administered as an oral tablet. The recommended dose in the instructions is 45 mg taken twice daily, approximately 12 hours apart, until disease progression or unacceptable toxicity occurs. Administration of a single 45 mg dose of bimetinib with a high-fat, high-calorie meal (consisting of approximately 150 calories of protein, 350 calories of carbohydrate, and 500 calories of fat) had no effect on bimetinib exposure in healthy subjects.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.